|
**Overview**: **Neuronal Autoantibodies Ultra Profile****Introduction**: The Neuronal Autoantibodies Ultra Profile is a diagnostic tool designed to screen for paraneoplastic syndromes using serum samples. Associated with conditions like paraneoplastic cerebellar degeneration and limbic encephalitis, these disorders present with neurological symptoms, confusion, and severe complications if untreated, particularly in individuals with suspected paraneoplastic syndromes. Per the 2023 Immunology guidelines, the test employs immunology with immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for neurological disorder screening in clinical settings. This diagnostic falls under neurological infection screening and targets individuals with suspected paraneoplastic syndromes, addressing the challenge of accurate autoantibody assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Neuronal Auto Pfl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by neurology labs, this test advanced paraneoplastic syndrome screening.**Purpose**: The test screens for 12 parameters including Anti-Hu to guide paraneoplastic syndrome assessment, assess neuronal autoantibodies, and inform treatment and prevention strategies.**Test Parameters**: 1. Anti-Hu, 2. Anti-Ri, 3. Anti-Yo, 4. Anti-CV2/CRMP5, 5. Anti-PNMA2 (Ma2/Ta), 6. Anti-Amphiphysin, 7. Anti-Recoverin, 8. Anti-SOX1, 9. Anti-Titin, 10. Anti-Zic4, 11. Anti-GAD65, 12. Anti-DNER.**Pretest Condition**: No fasting required; patients should report neurological symptoms, confusion, or recent paraneoplastic symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on neurological symptoms, confusion, prior paraneoplastic reactions, or family history of neurological disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated paraneoplastic syndromes including neurological damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent immunosuppressive therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible paraneoplastic syndromes, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in neurology or oncology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Imaging or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Immunology Guidelines 2023, Journal of Neurology 2024, Biochemistry 2025. |
